Get all your news in one place.
100's of premium titles.
One app.
Start reading
International Business Times
International Business Times
Business

Nanexa Stock Skyrockets More Than 100% After Signing Drug Deal With Wegovy Maker Novo Nordisk

Under the deal, Novo gets the right to use PharmaShell in as many as five development programs for peptide-based medicines targeting obesity, type 2 diabetes and other cardiometabolic diseases. (Credit: Sergei Gapon/AFP via Getty Images)

Shares of Swedish drug-delivery company Nanexa exploded higher Friday after the small biotech landed a licensing agreement worth as much as $1.33 billion with Novo Nordisk, the pharmaceutical heavyweight behind blockbuster obesity drugs Wegovy and Ozempic.

Nanexa shares surged more than 100% in Stockholm. the company announced Thursday evening that it had entered into a global exclusive licensing and collaboration agreement with Novo covering its PharmaShell drug-delivery technology.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.